Struma maligna pp 331-337 | Cite as

Das medulläre Schilddrüsenkarzinom im Follow-up

  • M. Manzl
  • G. Galvan
Conference paper

Zusammenfassung

Das medulläre Schilddrüsenkarzinom kommt anteilsmäßig in 5 bis 10% aller malignen Schilddrüsentumore vor (Hedinger 1989). Es sezerniert verschiedenste biologische Substanzen, wie das Kalzitonin und CEA, die als Tumormarker große Bedeutung haben, ferner Calcitonin Gene related Peptide (CGRP), Katakalzin, Somatostatin, Prostaglandin, Serotonin, ACTH, Beta-Endorphin, Beta-MSH, Substanz P, Histaminase, und Dopa-Decarboxylase, sowie Neuronspezifische Enolase (Stepanas 1979; Raue 1983, 1985, 1991; Nelkin 1989; Schifter 1989; Boultwood 1990).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bayraktar M, Gedik O, Akalin S, Usman A, Adalar N, Telatar F (1990) The effect of radioactive iodine treatment on thyroid C cells. Clin Endocrinol 33:625–630CrossRefGoogle Scholar
  2. 2.
    Benker W, Reiners C, Krause U, Bamberg M, Reinwein D (1988) Schilddrüsenkarzinome — aktuelle diagnostische und therapeutische Strategien. Internist 29:564–569PubMedGoogle Scholar
  3. 3.
    Bergholm U, Adami HO, Auer G, Bergström R, Bäckdahl M, Grimelius L, Hansson G, Ljungberg O, Wilander E, Swedish MTC Study Group (1989) Histopathologic characteristics and nuclear DNA content as prognistic factors in medullary thyroid carcinoma. Cancer 64:135–142PubMedCrossRefGoogle Scholar
  4. 4.
    Bergholm U, Adamit HO, Telenius-Berg M, Johansson H, Wilander E (1990) Incidence of sporadic und familial medullary thyroid carcinoma in Sweden 1959-through 1981. Acta Oncologica 29:9–15PubMedCrossRefGoogle Scholar
  5. 5.
    Börner W, Reiners C (1987) Schilddrüsenmalignome, Diagnostik, Therapie und Nachsorge. Schattauer, Stuttgart New YorkGoogle Scholar
  6. 6.
    Böttger T, Klupp J, Sorger K, Junginger T (1991) Therapie und Prognose des medullären Schilddrüsenkarzinoms. Med Klin 86:8–14Google Scholar
  7. 7.
    Boultwood J, Wynford-Thomas D, Richards P, Craig RK, Williams ED (1990) In situ analysis of calcitonin and CGRP expression in medullary thyroid carcinoma. Clin Endocrinol 33:381–390CrossRefGoogle Scholar
  8. 8.
    Calmettes C (1977) Multiple endocrine neoplasia Type 2, consens statement. Biomedica 27Google Scholar
  9. 9.
    Callmettes C, Guliana JM (1991) Medullary thyroid carcinoma. Colloque Inserm Libbey vol 211:255–264Google Scholar
  10. 10.
    Cance WG, Wells SA (1985) Multiple endocrine neoplasia type IIa. Curr Probl Surg 21:1Google Scholar
  11. 11.
    Carney JA, Sizemore GW, Hayles AB (1979) C-cell disease of the thyroid gland in multiple endocrine neoplasia type IIb. Cancer 44:2173–2183PubMedCrossRefGoogle Scholar
  12. 12.
    Clark SEM, Lazarus CR, Wraight P, Sampson C, Maisey MN (1988) Pentavalent (99mTc) DMSA, (131I) MIBG and (99mTc) MDP — an evaluation of three imgaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 29:33–38Google Scholar
  13. 13.
    Deftos LJ, Stein MF (1980) Radioiodine as an adjunct to the surgical treatment of medullary thyroid carcinoma. J Clin Endocrinol Metab 50:967–968PubMedCrossRefGoogle Scholar
  14. 14.
    Deftos LJ, Woloszczuk W, Kirsch I, Horvat G, Ulrich W, Neuhold N, Braun O, Reiner A, Skrikanta S, Kirsch K (1988) Medullary thyroid carcinomas express chromogranin A and a novel neuroendocrine protein recognized by monoclonal antibody HISL-19. Am J Med 85:780PubMedCrossRefGoogle Scholar
  15. 15.
    Easton DF, Ponder MA, Cummings T, Gagel RF, Hansen HH, Reichlin S, Tashjian AH, Telenius-Berg M, Ponder BAJ (1989) The clinical and screening age at onset distribution for the MEN 2 syndrome. Am Hum Genet 44:208–215Google Scholar
  16. 16.
    Ekman ET, Bergholm UZ, Bäckdahl M, Adami HO, Bergström R, Grimelius L, Auer G, Swedish Medullary Thyroid Cancer Study Group (1990) Nuclear DNA content and survival in medullary thyroid carcinoma. Cancer 65:511–519PubMedCrossRefGoogle Scholar
  17. 17.
    Gagel RF, Tashijan AH, Cummings T, Papathanasopoulus N, Kaplan MM, De Lellis RA, Wolfe HJ, Reichlin S (1988) The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18 year experience. N Engl J Med 318:478–484PubMedCrossRefGoogle Scholar
  18. 18.
    Geddie WR, Yvan C, Strawbridge HTG (1984) Medullary carcinoma of the thyroid in fine needle aspiration biopsies. Amer J clin Path 82:552–558Google Scholar
  19. 19.
    Heerden van JHA, Grant CS, Gharib H, Hay ID, Ilstrup DM (1990) Long term course of patients with persistent Hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 2212:295–401Google Scholar
  20. 20.
    Hellmann DE, Kartchner M, Antwerp van JD, et al. (1979) Radioiodine in the treatment of medullary carcinoma. J of Clin Endocrinol Metab 50:967–968Google Scholar
  21. 21.
    Hennessy JF, Wells SA, Ontjes DA, Cooper CW (1974) A comparison of pentagastrin injection and calcium infusion as provocative agents for the detection of medullary carcinoma of the thyroid. J of Clin Endocrinol 27:69–74Google Scholar
  22. 22.
    Hoefnagel CA, Delprat CC, Zanin D, van der Schoot JB (1988) New radionuclide tracers for the diagnosis an therapy of medullary carcinoma. Clin Nukl Med 13:159CrossRefGoogle Scholar
  23. 23.
    Kaplan M (1990) Progess in thyroid cancer. Endocr and Metab Clin of North America, vol 19, nr 3Google Scholar
  24. 24.
    Kohlwagen R (1991) Endokrinologie Inform Nr 6/15. Demeter VerlagGoogle Scholar
  25. 25.
    Kotzerke J, Schober O, Heintz P, Dralle H, Hundeshagen H (1986) Medulläres Schilddrüsencarcinom. Dtsch med Wschr 111:1140–1143PubMedCrossRefGoogle Scholar
  26. 26.
    Kujat C, Müller-Leisse, Fals S, Adam W, Pfannenstiel P (1990) Diagnostik des medullären Schilddrüsenkarzinoms. Dtsch med Wschr 115:1475–1479. Georg Thieme, Stuttgart New YorkGoogle Scholar
  27. 27.
    Kwekkeboom DJ, Lamberts SJW, Reubi JC, Oei Hy, Krenning EP (1992) Tumor localization using 111 Inoctreotide scintigraphy. Eur J Nucl Med 19/8:222–1Google Scholar
  28. 28.
    Langer HJ, Leicht E, Koch B, Biro G (1990) Ein zunehmend häufig erkannter Tumor. Therapiewoche 40:2620–2625Google Scholar
  29. 29.
    Mahler C, Verhelst J, Longueville De M, Harris A (1990) Long term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinology 33:261–269CrossRefGoogle Scholar
  30. 30.
    Mathew CGP, Easton DF, Nakamura Y, Ponder BAJ, MEN 2A International Collaborative Group (1991) Presymptomatic screening for multiple endocrine neoplasia type 2a with linked DNA markers. Lancet 337Google Scholar
  31. 31.
    Melvin KE (1986) Medullary carcinoma of the thyroid. In: Inbar SH, Braverman Le (eds) Werner’s the thyroidea fundamental and clinical text, 5th edn. Lippincott, Philadelphia, pp 1349–1362Google Scholar
  32. 32.
    Minne HW, Raue F (1987) Diagnostik des medullären Schilddrüsenkarzinoms. In: Bröner W, Reiners Ch (Hrsg) Schilddrüsenmalignome. Schattauer, Stuttgart New York, S 259–254Google Scholar
  33. 33.
    Miyauchi A, Endo K, Ohta K, Toirzuka K, Matsuzuka F, Kobayashi A, Kuma K, Maeda M (1986) 99m Tc(V) dimercaptosuccinic acid scintigraphy for medullary thyroid carcinoma. Wld J Surg 10:640CrossRefGoogle Scholar
  34. 34.
    Modigliani E, Cohen R, Joannidis S, Siame-Mourot C, Guliana JM, Charpentier G, Cassuto D, Bentata Pessayre M, Tabarin A, Roger P, Caron P, Giullausseae PJ, Lalau JD, Tournaire J, Bayard F, Aufevre P, James-Deidier A, Calmettes C (1992) Results of long-term continous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin Endocrin 36:183–186CrossRefGoogle Scholar
  35. 35.
    Nelkin BD, et al. (1989) The molecular biology of medullary thyroid carcinoma. JMA 261:3130CrossRefGoogle Scholar
  36. 36.
    Ponder BAJ (1984) Screening for familial medullary thyroid carcinoma: a review. Journ of the Royal Society of Medicine 77:585–594Google Scholar
  37. 37.
    Ponder BAJ, Coffey R, Pembrey ME, Gagel RF, Telenius-Berg M, Semple PF, Easton DF (1988) Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet I:397–400CrossRefGoogle Scholar
  38. 38.
    Raue F, Schmidt Gayk H, Ziegler R (1983) Tumormarker beim C-Zellkarzinom. Dtsch med Wschr 108:283–287PubMedCrossRefGoogle Scholar
  39. 39.
    Raue F (1985) Diagnostik des medullären Schilddrüsenkarzinoms. Dtsch med Wschr 110:1334PubMedCrossRefGoogle Scholar
  40. 40.
    Raue F, Winter J, Frank-Raue K, Lorenz D, Herfarth C, Ziegler R (1989) Diagnostik procedure before reoperation in patients with medullary thyroid carcinoma. Horm metab Res 21:Suppl 31Google Scholar
  41. 41.
    Raue F, Späth-Röger M, Winter J, Benker G, Buhr P, Dorn R, Dralle H, Frilling A, Herrmann J, Hörnig I, Meybier H, Klempa I, Kotzerke J, Pfannenstiel P, Reinwein D, Ritter M, Röher HD, Schober O, Schröder S, Seif F, Trede M, Vogt H, Wahl R, Zieger R (1990) Register für das medulläre Schilddrüsencarcinom in der Bundesrepublik Deutschland. Med Klinik 3:113–116Google Scholar
  42. 42.
    Raue F (1991) Medulläres Schilddrüsencarcinom. Endocrin Inform 6/15:224–225. Demeter VerlagGoogle Scholar
  43. 43.
    Roka R, Niederle B, Fritsch A, Krisch K, Schemper M (1982) Chirurgische Therapie des medullären Schilddrüsenkarzinoms. Dtsch med Wschr 107:132–138. G. Thieme-Verlag, Stuttgart New YorkPubMedCrossRefGoogle Scholar
  44. 44.
    Rougier P, Calmettes CC, Laplance A, Travagli JP, Lefebre M, Parmentier C, Milhaud G, Tubiana M (1983) The values of calcitonin and carcinomembryonic antigen in the treatment and management of nonfamilial medullary thyroid carcinoma. Cancer (Philad) 51:855CrossRefGoogle Scholar
  45. 45.
    Russel CF, Von Heerden JA, Sizemore GW, et al. (1983) The surgical management of thyroid carcinoma. Ann Surg 197(1):42–48Google Scholar
  46. 46.
    Saad MF, Ordonez G, Guido JJ, et al. (1984) The Prognostic value of calcitonin immunostaining in medullary carcinoma of the thyroid. J Clin Endocr Metab 59:850PubMedCrossRefGoogle Scholar
  47. 47.
    Samaan NA et al. (1988) Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrin Metab 67(4):801CrossRefGoogle Scholar
  48. 48.
    Schifter S (1989) Calcitonin gene related peptid and calcitonin as tumour markers in MEN 2 family screening. Clin Endocrin 30:263–270CrossRefGoogle Scholar
  49. 49.
    Schlumberger M, Gardet P, Vathaire de F, Sarrazin D, Travagli JP, Parmentier C (1991) External radiotherapy and chemotherapy in MTC patients. Medull Thyroid Carcinoma, Colloque Inserm 211:213–220Google Scholar
  50. 50.
    Sizemore GW, Go VLW (1979) Stimulation tests for diagnosis of medullary thyroid carcinoma. Mayo Clin Proc 50:53Google Scholar
  51. 51.
    Stepanas AV, Samaan NA, Hill CS, Hickey RC (1979) Medullary thyroid carcinoma — importance of serial serum calcitonin measurement. Cancer (Philad) 43:825CrossRefGoogle Scholar
  52. 52.
    Telander RL, Zimmermann D, Sizemore GW, Van Heerden JA, Gran CS (1989) Medullary carcinoma in children. Arch Surg 124:841PubMedCrossRefGoogle Scholar
  53. 53.
    Tennvall J, Björklung A, Möller T, Ranstam J, Akerman M (1985) Prognostic factors of papillary, follicular and medullary carcinomas of the thyroid gland. Acta Radiol Onkology 24:17CrossRefGoogle Scholar
  54. 54.
    Tubiana M (1981) Extern radiotherapy and radioiodine in the treatment of thyroid cancer. World J Surg 5:75–84PubMedCrossRefGoogle Scholar
  55. 55.
    Vasen H, Niewenhuijzen-Krusemann A, Berkel H, Beukers EKGM, Delprat CC, van Doom RG, Geerding RA, Haak HR, Hackeng WHL, Koppeschaar HPF, Krenning EP, Lamberts SWJ, Lekkerkerer FJF, Michels RPJ, Moers AMJ, Pieters GFFM, Wiersinga WM, Lips CJM (1987) Multiple endocrine neoplasia syndrome type 2: the value of screening and central registration. Am J Med 83:847–852PubMedCrossRefGoogle Scholar
  56. 56.
    Wahl RA, et al. (1988) Reintervention beim C-Zell-Karzinom. Wr klin Wschr 100:348Google Scholar
  57. 57.
    Wells SA, Dilley WG, Farndon JA, et al. (1985) Early diagnosis and treatment of medullary thyroid carcinoma. Arch Intern Med 145:1248–1252PubMedCrossRefGoogle Scholar
  58. 58.
    Woolner LB, Beahrs OH, Black BM, McConahey WM, Keating FR (1969) Long term survival rates. In: Cancer UICC Monographe series, vol 12:326–331, SpringerGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • M. Manzl
  • G. Galvan

There are no affiliations available

Personalised recommendations